Monday May 21 | Theflyonthewall.com
Rockwell Medical may benefit from competitor's troubles, says Rodman & Renshaw
After Fresenius reportedly improperly disclosed an elevated risk of cardiac arrest and death during therapy associated with the company's dialysis buffer concentrate product, Rodman & Renshaw believes that the report may highlight the benefits of Rockwell's citrate-based buffer, CitraPure.
Monday May 21 | Sys-Con Media
Rockwell Medical Announces European Patent Issuance for Proprietary SFP Formulation
Mr. Robert L. Chioini, Chairman and CEO, stated, "We are pleased to receive this patent protection for the European Union.
Rockwell Medical Technologies Schedules Earnings Conference Call
HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia WIXOM, MI, May 1, 2012 -- Rockwell Medical , a fully-integrated biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with innovative products ... (more)
Rockwell Medical Completes Patient Enrollment in PRIME Clinical Study
Robert L. Chioini, Chairman and CEO of Rockwell, stated, "We are excited to achieve another important milestone in our SFP clinical development.